AAV vectors encoding malarial antigens stimulate antigen-specific immunity but do not protect from parasite infection

Vaccine

Volumn 25, Issue 6, 2007, Pages 1014-1022

  Logan, Grant J ^a   Wang, Lina ^b   Zheng, Maolin ^a   Cunningham, Sharon C ^a   Coppel, Ross L ^b   Alexander, Ian E ^a,c  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

AAV; Genetic vaccines; Malaria

Indexed keywords

ADENOVIRUS VECTOR; FREUND ADJUVANT; MEROZOITE SURFACE PROTEIN 4; MEROZOITE SURFACE PROTEIN 5; PARASITE ANTIGEN; PLASMID DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DNA MODIFICATION; DRUG EFFICACY; DRUG POTENCY; EXPERIMENTAL INFECTION; FEMALE; GENETIC CODE; GENETIC IMMUNIZATION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; INFECTION PREVENTION; INFECTION RESISTANCE; MALARIA FALCIPARUM; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS RECOMBINANT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; ANTIGENS, PROTOZOAN; DEPENDOVIRUS; EPITOPES; FEMALE; GENETIC VECTORS; HELA CELLS; HUMANS; INJECTIONS, INTRAMUSCULAR; MALARIA; MALARIA VACCINES; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; PROTOZOAN PROTEINS;

EID: 33845576104     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.09.072     Document Type: Article

References (49)

1. Tang D.C., DeVit M., and Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 356 6365 (1992) 152-154
2. Gardner M.J., Hall N., Fung E., White O., Berriman M., Hyman R.W., et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419 6906 (2002) 498-511
3. Dullaers M., and Thielemans K. From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy. J Gene Med 8 1 (2006) 3-17
4. Griesenbach U., Inoue M., Hasegawa M., and Alton E.W. Sendai virus for gene therapy and vaccination. Curr Opin Mol Ther 7 4 (2005) 346-352
5. Tatsis N., and Ertl H.C. Adenoviruses as vaccine vectors. Mol Ther 10 4 (2004) 616-629
6. Wang C.H., Liu D.W., Tsao Y.P., Xiao X., and Chen S.L. Can genes transduced by adeno-associated virus vectors elicit or evade an immune response?. Arch Virol 149 1 (2004) 1-15
7. Yang Y., Haecker S.E., Su Q., and Wilson J.M. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum Mol Genet 5 11 (1996) 1703-1712
8. Kessler P.D., Podsakoff G.M., Chen X., McQuiston S.A., Colosi P.C., Matelis L.A., et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 93 (1996) 14082-14087
9. Xiao X., Li J., and Samulski R.J. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 70 11 (1996) 8098-8108
10. Snyder R.O., Spratt S.K., Lagarde C., Bohl D., Kaspar B., Sloan B., et al. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther 8 16 (1997) 1891-1900
11. Fisher K.J., Jooss K., Alston J., Yang Y., Haecker S.E., High K., et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 3 3 (1997) 306-312
12. Ramshaw I.A., and Ramsay A.J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 21 4 (2000) 163-165
13. Moore A.C., and Hill A.V. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol Rev 199 (2004) 126-143
14. Monahan P.E., and Samulski R.J. Adeno-associated virus vectors for gene therapy: more pros than cons?. Mol Med Today 6 11 (2000) 433-440
15. Chao H., Liu Y., Rabinowitz J., Li C., Samulski R.J., and Walsh C.E. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2 6 (2000) 619-623
16. Blankinship M.J., Gregorevic P., Allen J.M., Harper S.Q., Harper H., Halbert C.L., et al. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol Ther 10 4 (2004) 671-678
17. Jooss K., Yang Y., Fisher K.J., and Wilson J.M. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 72 5 (1998) 4212-4223
18. Zaiss A.K., Liu Q., Bowen G.P., Wong N.C., Bartlett J.S., and Muruve D.A. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 76 9 (2002) 4580-4590
19. Sarukhan A., Soudais C., Danos O., and Jooss K. Factors influencing cross-presentation of non-self antigens expressed from recombinant adeno-associated virus vectors. J Gene Med 3 3 (2001) 260-270
20. Herzog R.W., Hagstrom J.M., Kung S., Tai S.J., Wilson J.M., Fisher K.J., et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 94 (1997) 5804-5809
21. Song S., Morgan M., Ellis T., Poirier A., Chesnut K., Wang J., et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA 95 24 (1998) 14384-14388
22. Wang L., Dobrzynski E., Schlachterman A., Cao O., and Herzog R.W. Systemic protein delivery by muscle-gene transfer is limited by a local immune response. Blood 105 11 (2005) 4226-4234
23. Gao G., Lebherz C., Weiner D.J., Grant R., Calcedo R., McCullough B., et al. Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 103 9 (2004) 3300-3302
24. Chenuaud P., Larcher T., Rabinowitz J.E., Provost N., Cherel Y., Casadevall N., et al. Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 103 9 (2004) 3303-3304
25. Scherer W.F., Syverton J.T., and Gey G.O. Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exp Med 97 5 (1953) 695-710
26. Graham F.L., Smiley J., Russell W.C., and Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36 1 (1977) 59-74
27. Marshall V.M., Silva A., Foley M., Cranmer S., Wang L., McColl D.J., et al. A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains an epidermal growth factor-like domain. Infect Immun 65 11 (1997) 4460-4467
28. Kedzierski L., Black C.G., and Coppel R.L. Characterization of the merozoite surface protein 4/5 gene of Plasmodium berghei and Plasmodium yoelii. Mol Biochem Parasitol 105 1 (2000) 137-147
29. Zolotukhin S., Potter M., Hauswirth W.W., Guy J., and Muzyczka N. A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol 70 7 (1996) 4646-4654
30. Xiao X., Li J., and Samulski R.J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72 3 (1998) 2224-2232
31. Gorman C. High efficiency gene transfer into mammalian cells. In: Glover D.M. (Ed). DNA cloning (1985), IRL Press, Oxford, Washington DC 143-165
32. Veldwijk M.R., Topaly J., Laufs S., Hengge U.R., Wenz F., Zeller W.J., et al. Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol Ther 6 2 (2002) 272-278
33. Black C.G., Wang L., Hibbs A.R., Werner E., and Coppel R.L. Identification of the Plasmodium chabaudi homologue of merozoite surface proteins 4 and 5 of Plasmodium falciparum. Infect Immun 67 5 (1999) 2075-2081
34. Wang L., Kedzierski L., Schofield L., and Coppel R.L. Influence of glycosylphosphatidylinositol anchorage on the efficacy of DNA vaccines encoding Plasmodium yoelii merozoite surface protein 4/5. Vaccine 23 32 (2005) 4120-4127
35. Wang L., Menting J.G., Black C.G., Stowers A., Kaslow D.C., Hoffman S.L., et al. Differences in epitope recognition, isotype and titer of antisera to Plasmodium falciparum merozoite surface protein 4 raised by different modes of DNA or protein immunization. Vaccine 19 7-8 (2000) 816-824
36. Kedzierski L., Black C.G., and Coppel R.L. Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge. Infect Immun 68 10 (2000) 6034-6037
37. Kedzierski L., Black C.G., Stowers A.W., Goschnick M.W., Kaslow D.C., and Coppel R.L. Comparison of the protective efficacy of yeast-derived and Escherichia coli-derived recombinant merozoite surface protein 4/5 against lethal challenge by Plasmodium yoelii. Vaccine 19 32 (2001) 4661-4668
38. Manning W.C., Paliard X., Zhou S., Bland M.P., Lee A.Y., Hong K., et al. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. J Virol 71 10 (1997) 7960-7962
39. Xin K.Q., Urabe M., Yang J., Nomiyama K., Mizukami H., Hamajima K., et al. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum Gene Ther 12 9 (2001) 1047-1061
40. Xin K.Q., Ooki T., Mizukami H., Hamajima K., Okudela K., Hashimoto K., et al. Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses. Hum Gene Ther 13 13 (2002) 1571-1581
41. Gallez-Hawkins G., Li X., Franck A.E., Thao L., Lacey S.F., Diamond D.J., et al. DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice. Vaccine 23 6 (2004) 819-826
42. Johnson P.R., Schnepp B.C., Connell M.J., Rohne D., Robinson S., Krivulka G.R., et al. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 79 2 (2005) 955-965
43. Liu D.W., Tsao Y.P., Kung J.T., Ding Y.A., Sytwu H.K., Xiao X., et al. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol 74 6 (2000) 2888-2894
44. Ponnazhagan S., Mahendra G., Lima J., Aldrich W.A., Jenkins C.B., Ren C., et al. Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant. Hum Gene Ther 15 9 (2004) 856-864
45. Han W., Wind-Rotolo M., Kirkman R.L., and Morrow C.D. Inhibition of human immunodeficiency virus type 1 replication by siRNA targeted to the highly conserved primer binding site. Virology 330 1 (2004) 221-232
46. During M.J., Symes C.W., Lawlor P.A., Lin J., Dunning J., Fitzsimons H.L., et al. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science 287 5457 (2000) 1453-1460
47. Arruda V.R., Schuettrumpf J., Herzog R.W., Nichols T.C., Robinson N., Lotfi Y., et al. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood 103 1 (2004) 85-92
48. Cordier L., Gao G.P., Hack A.A., McNally E.M., Wilson J.M., Chirmule N., et al. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum Gene Ther 12 2 (2001) 205-215
49. Kedzierski L., Black C.G., Goschnick M.W., Stowers A.W., and Coppel R.L. Immunization with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii. Infect Immun 70 12 (2002) 6606-6613